Just because a business does not make any money, does not mean that the stock will go down. Indeed, NeuroMetrix (NASDAQ:NURO) stock is up 920% in the last year, providing strong gains for shareholders ...
Some NeuroMetrix, Inc. (NASDAQ:NURO) shareholders are probably rather concerned to see the share price fall 55% over the last three months. But that cannot eclipse the spectacular share price rise ...
WOBURN, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (“NeuroMetrix” or the “Company”) (Nasdaq: NURO) today announced it has entered into a ...
On December 2, Bradley Fluegel notified the Board of Directors of NeuroMetrix (NURO), of his decision to resign from the Board and as a member of the Board’s Audit Committee, effective as of December ...
Nerve stimulation company electroCore has signed an agreement to acquire NeuroMetrix and its Quell wearable device aimed at fibromyalgia and chronic pain. The deal, valued at about $9 million in cash ...
After spending much of last year shifting resources toward an update to its DPNCheck screening device for peripheral neuropathy, NeuroMetrix is ready to reap the rewards of that investment. The ...
The NeuroMetrix team has proven that it can successfully commercialize medical device products through its highly capable team, including its sales force. I personally look forward to carrying out the ...
Shares have lost half their value since this spring as a number of insurers have said they would restrict reimbursement for the company's nerve tests. But some investors are betting doctors who find ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback